Journal of Cardiac Failure
-
Publication Venue For
-
Do PRO measures function the same way for all individuals with heart failure?
2022
-
Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial.
2022
-
Advancing Our Common Purpose Through "Coopetition"..
28:881-882.
2022
-
Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure..
28:916-923.
2022
-
Emerging Implantable-Device Technology for Patients at the Intersection of Electrophysiology and Heart Failure Interdisciplinary Care..
28:991-1015.
2022
-
Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study..
28:935-946.
2022
-
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure..
28:e1-e167.
2022
-
2022 American College of Cardiology/American Heart Association/Heart Failure Society of America Guideline for the Management of Heart Failure: Executive Summary..
28:810-830.
2022
-
Discordance of Pressure and Volume: Potential Implications for Pressure-Guided Remote Monitoring in Heart Failure..
28:870-872.
2022
-
International Collaborations in Heart Failure: JCF in Latin America..
28:695-696.
2022
-
Paying Homage to the Power of Proteomics: Insights Into Obesity and Heart Failure From the HOMAGE Trial..
28:787-788.
2022
-
Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure.
2022
-
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial.
2022
-
Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure.
2022
-
Donation After Circulatory Death in Heart Transplantation: History, Outcomes, Clinical Challenges, and Opportunities to Expand the Donor Pool.
2022
-
#WordsMatter Continued: Moving from "Candidacy" To "Benefit Derived"..
28:517-518.
2022
-
Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure..
28:554-563.
2022
-
Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.
2022
-
#ConstructivelyDisruptive - Breaking Molds at JCF..
28:351-352.
2022
-
Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry..
28:370-384.
2022
-
Exception-Status Listing: A Critical Pathway to Heart Transplantation for Adults With Congenital Heart Diseases..
28:415-421.
2022
-
Innovations in Heart Transplantation: A Review..
28:467-476.
2022
-
Sex Differences in Heart Failure..
28:477-498.
2022
-
Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial.
2022
-
Contemporary Nationwide Heart Transplantation and Left Ventricular Assist Device Outcomes in Patients with Histories of Bariatric Surgery..
28:330-333.
2022
-
Heart Month - A Historical Look and Simple "Walk" of Acknowledgement in the Present..
28:169-170.
2022
-
Leveraging Multiple Biomarkers to Assess Risk of Acute Heart Failure: Is More Better?.
28:234-236.
2022
-
Polypharmacy in Palliative Care for Advanced Heart Failure: The PAL-HF Experience..
28:334-338.
2022
-
The Road Not Yet Traveled: Distinction in Critical Care Cardiology through the Advanced Heart Failure and Transplant Cardiology Training Pathway..
28:339-342.
2022
-
Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction..
28:191-201.
2022
-
Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study.
2022
-
HCV Positive Allograft Use in Heart Transplant: A Silver Lining to an Epidemic..
28:42-43.
2022
-
Older Patients With Acute Decompensated Heart Failure Who Live Alone: An Analysis From the REHAB-HF Trial..
28:161-163.
2022
-
Pericardial Adipose Tissue Volume and Left Ventricular Assist Device-Associated Outcomes..
28:149-153.
2022
-
Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program..
28:13-20.
2022
-
The JCF Reviewer Mentorship Program..
28:1-2.
2022
-
Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction.
2021
-
EXPANDing the Donor Pool: Quantifying the Potential Impact of a Portable Organ-Care System for Expanded Criteria Heart Donation..
27:1462-1465.
2021
-
JCF Year-In-Review 2021 and the Path Forward..
27:1307-1309.
2021
-
Patterns of Change in Individual Domains of the Kansas City Cardiomyopathy Questionnaire With a Palliative Care Intervention for Patients With Advanced Heart Failure: Insights from PAL-HF..
27:1476-1478.
2021
-
Representativeness of the VICTORIA Trial Population in Clinical Practice: Analysis of the PINNACLE Registry..
27:1374-1381.
2021
-
The Impact of Depression on Outcomes in Patients With Heart Failure and Reduced Ejection Fraction Treated in the GUIDE-IT Trial..
27:1359-1366.
2021
-
Universal Definition and Classification of Heart Failure: Pharmacists' Perspective: Optimizing Guideline-Directed Medical Therapy and Educating Stakeholders..
27:1310-1312.
2021
-
Drugs of Abuse and Heart Failure..
27:1260-1275.
2021
-
Estimated Glomerular Filtration Rate Variability in Patients With Heart Failure and Chronic Kidney Disease..
27:1175-1184.
2021
-
Following Our Hearts: Prioritizing Self-care and Wellness..
27:1163-1164.
2021
-
De Novo vs Acute-on-Chronic Presentations of Heart Failure-Related Cardiogenic Shock: Insights from the Critical Care Cardiology Trials Network Registry..
27:1073-1081.
2021
-
Physician Perspective..
27:1157.
2021
-
The Nexus of Heart Failure and Critical Care Cardiology..
27:1041.
2021
-
Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends..
27:942-948.
2021
-
Overcoming Inertia: Announcing Double Blinded Reviews at JCF..
27:923-924.
2021
-
Physical Functioning in Heart Failure With Preserved Ejection Fraction..
27:1002-1016.
2021
-
Language Matters: Understanding Barriers to Medication Adherence to Better Tailor Heart Failure Care..
27:825.
2021
-
Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation..
27:857-864.
2021
-
Sacubitril/Valsartan Initiation and Postdischarge Adherence Among Patients Hospitalized for Heart Failure..
27:826-836.
2021
-
Profile of Patients Hospitalized for Heart Failure Who Leave Against Medical Advice..
27:747-755.
2021
-
The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure..
27:808-811.
2021
-
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial.
2021
-
Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy..
27:670-676.
2021
-
Remembering the Calling - Where Patients and Caregivers Are Front and Center..
27:621.
2021
-
The Cost-Effectiveness of Palliative Care: Insights from the PAL-HF Trial..
27:662-669.
2021
-
Clinical Outcome Predictions for the VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: VICTORIA Outcomes Model.
2021
-
Association between Respiratory Failure and Clinical Outcomes in Patients with Acute Heart Failure: Analysis of 5 Pooled Clinical Trials..
27:602-606.
2021
-
Comparison of Dyspnea Measurement Instruments in Acute Heart Failure: The DYSPNEA-AHF Pilot Study..
27:607-609.
2021
-
Reaping from Reciprocity: the Mentor-Mentee Relationship..
27:507-508.
2021
-
Contemplation from Our Hearts: A Call to Shift From Failure to Function..
27:385.
2021
-
Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis..
27:477-485.
2021
-
The Universal Definition of Heart Failure: Perspectives from Diverse Stakeholders..
27:386.
2021
-
Cognition, Physical Function, and Quality of Life in Older Patients With Acute Decompensated Heart Failure..
27:286-294.
2021
-
Contemporary Use of Venoarterial Extracorporeal Membrane Oxygenation: Insights from the Multicenter RESCUE Registry..
27:327-337.
2021
-
Diversity, Equity and Inclusion at the Journal of Cardiac Failure..
27:263-264.
2021
-
Fibroblast Growth Factor 23 and Exercise Capacity in Heart Failure with Preserved Ejection Fraction..
27:309-317.
2021
-
Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure..
27:297-308.
2021
-
Shining a light on the vulnerable intersection of pregnancy and heart failure..
27:129.
2021
-
Building a Heart Failure Clinic: A Practical Guide from the Heart Failure Society of America..
27:2-19.
2021
-
The Future of the Journal of Cardiac Failure: A Reinvigorated Focus on People, Partnerships and Presentation..
27:1.
2021
-
Characterization of the Progression From Ambulatory to Hospitalized Heart Failure With Preserved Ejection Fraction..
26:919-928.
2020
-
Lifting Coronavirus Disease-19 Shelter-in-Place Restrictions: Impact on Heart Failure Hospitalizations in Northeast Georgia..
26:806-807.
2020
-
Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure..
26:727-732.
2020
-
Changes in Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey..
26:635-636.
2020
-
Virtual Visits for Care of Patients with Heart Failure in the Era of COVID-19: A Statement from the Heart Failure Society of America..
26:448-456.
2020
-
Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study..
26:371-380.
2020
-
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial..
26:429-437.
2020
-
Impact of Continuous Flow Left Ventricular Assist Device Therapy on Chronic Kidney Disease: A Longitudinal Multicenter Study..
26:333-341.
2020
-
2020 ACC/HFSA/ISHLT Lifelong Learning Statement for Advanced Heart Failure and Transplant Cardiology Specialists: A Report of the ACC Competency Management Committee..
26:254-269.
2020
-
Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial..
26:270-275.
2020
-
Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction..
26:101-107.
2020
-
Outcomes of Severely Obese Patients Supported by a Centrifugal-Flow Left Ventricular Assist Device..
26:120-127.
2020
-
Association of Wolff-Parkinson-White With Left Ventricular Noncompaction Cardiomyopathy in Children..
25:1004-1008.
2019
-
PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure..
25:1009-1011.
2019
-
Trajectories of Changes in Renal Function in Patients with Acute Heart Failure..
25:866-874.
2019
-
Corrigendum to "Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America" Journal of Cardiac Failure Vol. 25 No. 8, pp. 584-619..
25:851.
2019
-
Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF..
25:703-711.
2019
-
A Balancing Act: Preserving Renal Function and the Need for Decongestion..
25:643-644.
2019
-
African Americans With Advanced Heart Failure Are More Likely to Die in a Health Care Facility Than at Home or in Hospice: An Analysis From the PAL-HF Trial..
25:693-694.
2019
-
Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America..
25:584-619.
2019
-
Nutrition, Obesity, and Cachexia in Patients With Heart Failure: A Consensus Statement from the Heart Failure Society of America Scientific Statements Committee..
25:380-400.
2019
-
Relationship of Liver Stiffness With Congestion in Patients Presenting With Acute Decompensated Heart Failure..
25:176-187.
2019
-
Response to Letter to the Editor by Dr Kobayashi and Colleagues..
25:141.
2019
-
In-Hospital and Three-Year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry..
24:842-848.
2018
-
A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials..
24:783-792.
2018
-
Calculated Estimates of Plasma Volume in Patients With Chronic Heart Failure-Comparison With Measured Volumes..
24:553-560.
2018
-
Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization..
24:542-549.
2018
-
Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial..
24:512-519.
2018
-
Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort..
24:496-503.
2018
-
Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials..
24:428-438.
2018
-
A Contemporary Analysis of Heart Transplantation and Bridge-to-Transplant Mechanical Circulatory Support Outcomes in Cardiac Sarcoidosis..
24:384-391.
2018
-
Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study..
24:255-265.
2018
-
When Complementary and Alternative Medicine Meets Heart Failure-a Modest Proposal..
24:202-203.
2018
-
Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study..
24:33-42.
2018
-
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America..
23:628-651.
2017
-
2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee..
23:492-511.
2017
-
Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy..
23:340-344.
2017
-
Patients Commonly Believe Their Heart Failure Hospitalizations Are Preventable and Identify Worsening Heart Failure, Nonadherence, and a Knowledge Gap as Reasons for Admission..
23:252-256.
2017
-
The Challenges of Bedside-to-Bench Research in Pediatric Cardiology..
23:81-82.
2017
-
Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF..
22:884-890.
2016
-
Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score..
22:853-858.
2016
-
Response: Proposing and Meeting the Need for Interdisciplinary Cardio-Oncology Subspecialty Training by Sherry-Ann Brown, MD, PhD and Nicole Sandhu, MD, PhD..
22:936.
2016
-
Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials..
22:875-883.
2016
-
Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS..
22:815-822.
2016
-
Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy..
22:797-805.
2016
-
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America..
22:659-669.
2016
-
Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes..
22:738-742.
2016
-
Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS..
22:672-679.
2016
-
Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group..
22:618-627.
2016
-
The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study..
22:589-597.
2016
-
Lack of Relationship Between Serum Cardiac Troponin I Level and Giant Cell Myocarditis Diagnosis and Outcomes..
22:583-585.
2016
-
Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial..
22:485-491.
2016
-
Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial..
22:545-547.
2016
-
Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty..
22:465-471.
2016
-
Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial..
22:409-416.
2016
-
Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow?.
22:182-189.
2016
-
Trends in Heart Failure Clinical Trials From 2001-2012..
22:171-179.
2016
-
Elevated Cardiac Troponin I in Preservation Solution Is Associated With Primary Graft Dysfunction..
22:158-162.
2016
-
Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure..
22:26-32.
2016
-
Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact..
21:741-750.
2015
-
Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee..
21:674-693.
2015
-
Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions..
21:667-673.
2015
-
Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients..
21:608-609.
2015
-
Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee..
21:519-534.
2015
-
Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study..
21:179-188.
2015
-
The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure..
21:233-239.
2015
-
Cardiac contractility modulation: the next cardiac resynchronization therapy or another renal sympathetic denervation?.
21:24-26.
2015
-
Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group..
21:27-43.
2015
-
Exercise training and pacing status in patients with heart failure: results from HF-ACTION..
21:60-67.
2015
-
Functional status in left ventricular assist device-supported patients: a literature review..
20:973-983.
2014
-
Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION..
20:541-547.
2014
-
Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study..
20:407-413.
2014
-
High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial..
20:319-326.
2014
-
Infection and noncardiovascular death in the elderly-Heart failure's dirty little secret..
20:181-182.
2014
-
ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons..
20:65-90.
2014
-
Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices..
20:91-97.
2014
-
Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation..
20:23-30.
2014
-
Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION..
20:38-44.
2014
-
Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF..
19:611-620.
2013
-
Biomarker-guided therapies in heart failure: a forum for unified strategies..
19:592-599.
2013
-
Acute decompensated heart failure: update on new and emerging evidence and directions for future research..
19:371-389.
2013
-
Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims..
19:401-407.
2013
-
Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure..
19:408-415.
2013
-
Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy..
18:837-844.
2012
-
The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial..
18:515-523.
2012
-
The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy..
18:524-533.
2012
-
Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: findings from GWTG-HF..
18:471-477.
2012
-
Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?.
18:413-422.
2012
-
Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee..
18:265-281.
2012
-
Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network..
18:176-182.
2012
-
Change in intrathoracic impedance measures during acute decompensated heart failure admission: results from the Diagnostic Data for Discharge in Heart Failure Patients (3D-HF) Pilot Study..
18:107-112.
2012
-
Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee..
18:94-106.
2012
-
Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases..
18:74-81.
2012
-
Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific)..
18:82-88.
2012
-
Predictors of hospital length of stay in heart failure: findings from Get With the Guidelines..
17:649-656.
2011
-
The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure..
17:613-621.
2011
-
Use and predictors of heart failure disease management referral in patients hospitalized with heart failure: insights from the Get With the Guidelines Program..
17:431-439.
2011
-
Regional variations in physicians' attitudes and recommendations surrounding implantable cardioverter-defibrillators..
17:318-324.
2011
-
Response to inhaled nitric oxide predicts survival in patients with pulmonary hypertension..
17:265-271.
2011
-
Coping effectively with heart failure (COPE-HF): design and rationale of a telephone-based coping skills intervention..
17:201-207.
2011
-
Highlights of the 2010 scientific sessions of the Heart Failure Society of America, San Diego, California, September 12-15, 2010..
17:92-99.
2011
-
Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: findings from IMPROVE HF..
16:940-949.
2010
-
The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study..
16:714-719.
2010
-
HFSA 2010 Comprehensive Heart Failure Practice Guideline..
16:e1-194.
2010
-
Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure..
16:230-238.
2010
-
Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function..
16:25-35.
2010
-
Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization..
16:69-75.
2010
-
Relationship between anemia and health care costs in heart failure..
15:843-849.
2009
-
Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation..
15:819-827.
2009
-
The heart failure clinic: a consensus statement of the Heart Failure Society of America..
14:801-815.
2008
-
Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF)..
14:777-784.
2008
-
High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization..
14:661-669.
2008
-
The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment..
14:631-640.
2008
-
A global ranking approach to end points in trials of mechanical circulatory support devices..
14:368-372.
2008
-
Microvascular disease and cardiomyopathy..
13:792.
2007
-
Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF..
13:722-731.
2007
-
Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study..
13:360-364.
2007
-
Predictors of delivery of hospital-based heart failure patient education: a report from OPTIMIZE-HF..
13:189-198.
2007
-
Diagnostic characteristics of combining phonocardiographic third heart sound and systolic time intervals for the prediction of left ventricular dysfunction..
13:18-24.
2007
-
Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial..
13:8-13.
2007
-
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial..
12:684-688.
2006
-
Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading..
12:360-368.
2006
-
What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial..
12:336-342.
2006
-
High-sensitivity C-reactive protein and parameters of left ventricular dysfunction..
12:61-65.
2006
-
Measures of Ventricular Arterial Elastance
-
Percutaneous Hemodynamic support (impella) in patients with advanced heart failure and/or cardiogenic shock not eligible to PROTECT II Trial (Abstract).
18:S101-S101.
2012
-
Is Thoracic Impedance Cardiography ready to replace invasive techniques for measuring cardiac indices? (Abstract).
S107-S108.
2010
-
Calcitonin Gene-Related Peptide as a Potential Marker of Compensation in Patients with Acute Heart Failure Exacerbations (Abstract).
15 (Suppl):S37-S37.
2009
-
Diastolic Dysfunction (DD) Is a Useful Marker to Risk Stratify Patients with Frequent COPD Exacerbations and Normal Left Ventricular Ejection Fraction (LVEF) (Abstract).
14:S86-S86.
2008
-
Renal function and thyroid status in heart failure (Abstract).
13 (Suppl 2):S95-S95.
2007
-
Overview of acute decompensated heart failure in Argentina: Lessons learned from five registries during the last decade (Abstract).
11 (6 Suppl):S186-S186.
2005
-
Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis.
2017
-
Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure.
2016